Oregon Telemeds approach includes: A comprehensive medical intake and screening process Evaluation for contraindications and potential risks Clear education about expected benefits and side effects Ongoing monitoring to assess effectiveness and tolerance Telehealth does not mean reduced care
Key dates: TRIUMPH-1 and TRIUMPH-2 results (mid-2026), head-to-head vs tirzepatide (December 2026), and any NDA filing announcement from Eli Lilly
Weight loss as cardiovascular medicine Retatrutide produces the most dramatic weight loss of any peptide studied to date, with mean reductions of 24 to 26% body weight at the highest doses
High-quality protein sources include lean meats, fish, eggs, dairy products, legumes, and plant-based alternatives
As GLP-1 has been implicated as a mediator in the putative gutrenal axis (a rapid-acting feed-forward loop that regulates postprandial fluid and electrolyte homeostasis), direct actions on the kidney have been proposed